DK1794313T3 - Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein - Google Patents

Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein

Info

Publication number
DK1794313T3
DK1794313T3 DK05755789.4T DK05755789T DK1794313T3 DK 1794313 T3 DK1794313 T3 DK 1794313T3 DK 05755789 T DK05755789 T DK 05755789T DK 1794313 T3 DK1794313 T3 DK 1794313T3
Authority
DK
Denmark
Prior art keywords
fyn
syk
screenings
abl
combination
Prior art date
Application number
DK05755789.4T
Other languages
Danish (da)
English (en)
Inventor
Malcolm Ward
Helen Byers
Brian Henry Anderton
Pascal Derkinderen
Christopher Hugh Reynolds
Ritchie Williamson
Original Assignee
Proteome Sciences Plc
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences Plc, King S College London filed Critical Proteome Sciences Plc
Application granted granted Critical
Publication of DK1794313T3 publication Critical patent/DK1794313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
DK05755789.4T 2004-06-21 2005-06-21 Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein DK1794313T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58090104P 2004-06-21 2004-06-21
PCT/GB2005/002475 WO2005123048A2 (en) 2004-06-21 2005-06-21 Screening methods using c-abl, fyn and syk in combination with tau protein

Publications (1)

Publication Number Publication Date
DK1794313T3 true DK1794313T3 (da) 2013-07-22

Family

ID=35064772

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05755789.4T DK1794313T3 (da) 2004-06-21 2005-06-21 Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein

Country Status (8)

Country Link
US (3) US8367360B2 (enExample)
EP (2) EP1794313B1 (enExample)
JP (3) JP5058792B2 (enExample)
AU (1) AU2005253776B8 (enExample)
CA (1) CA2571614C (enExample)
DK (1) DK1794313T3 (enExample)
ES (1) ES2415665T3 (enExample)
WO (1) WO2005123048A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506302A (ja) * 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
WO2008009000A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
WO2008057599A2 (en) * 2006-11-10 2008-05-15 Intra-Cellular Therapies, Inc. Methods for the treatment of abeta related disorders and compositions therefor
WO2008145789A1 (es) * 2007-05-28 2008-12-04 Pontificia Universidad Catolica De Chile Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc).
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011044537A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
WO2013148283A1 (en) 2012-03-30 2013-10-03 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR101582852B1 (ko) * 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
JP2014147365A (ja) * 2013-02-04 2014-08-21 Osaka City Univ オリゴヌクレオチド構造体および遺伝子発現抑制方法
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
TWI657819B (zh) * 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
KR20160127825A (ko) * 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
US20180311236A1 (en) * 2015-10-28 2018-11-01 Ab Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
JP2017131191A (ja) * 2016-01-29 2017-08-03 国立大学法人京都大学 疾患の予防及び／又は治療剤のスクリーニング方法
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
WO2018216705A1 (ja) * 2017-05-23 2018-11-29 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
JP7197864B2 (ja) * 2017-05-31 2022-12-28 公立大学法人名古屋市立大学 アルツハイマー病バイオマーカー
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
BR112020018365A2 (pt) * 2018-03-13 2020-12-29 Janssen Pharmaceutica Nv Oligonucleotídeos modificados e métodos para uso em tauopatias
CN113272308B (zh) 2018-11-20 2025-03-18 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN110702665B (zh) * 2019-11-14 2022-03-22 济南大学 一种纸基耦合增强拉曼传感器制备及其在大田软海绵酸检测中的应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2024064729A1 (en) * 2022-09-20 2024-03-28 University Of Virginia Patent Foundation Syk activators and inhibitors in neurodegenerative diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Also Published As

Publication number Publication date
CA2571614C (en) 2016-12-06
JP5058792B2 (ja) 2012-10-24
US20080103107A1 (en) 2008-05-01
US20160186233A1 (en) 2016-06-30
EP1794313A2 (en) 2007-06-13
EP2441847A2 (en) 2012-04-18
US20130123133A1 (en) 2013-05-16
AU2005253776B2 (en) 2011-09-29
CA2571614A1 (en) 2005-12-29
AU2005253776A1 (en) 2005-12-29
EP2441847B1 (en) 2015-09-23
EP1794313B1 (en) 2013-05-15
EP2441847A3 (en) 2012-07-25
AU2005253776A8 (en) 2012-02-02
AU2005253776B8 (en) 2012-02-02
JP2008504022A (ja) 2008-02-14
ES2415665T3 (es) 2013-07-26
WO2005123048A2 (en) 2005-12-29
US8367360B2 (en) 2013-02-05
WO2005123048A3 (en) 2006-03-30
JP2012024094A (ja) 2012-02-09
JP2014198054A (ja) 2014-10-23
JP5668201B2 (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
FI20041323A0 (fi) Analysoija, järjestelmä ja menetelmä toivotun käyttäjäjoukon määrittämiseksi
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK1768657T3 (da) Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK1725253T3 (da) Medikamenter og fremgangsmåder til behandling af hovedpine
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
NO20042409L (no) System og metode for detektering av tilstedevaerelse.
DE602005027205D1 (de) Nahrungsmittelzusammensetzungen und damit in zusammenhang stehende verfahren
FI20040351L (fi) Mittausmenetelmä ja -järjestely
DK1756536T3 (da) Fremgangsmåde og system til vurdering af prøver
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
DE602004026422D1 (de) Datenbank-datenwiederherstellungssystem und -verfahren
DK1918385T3 (da) Fremgangsmåde til detektion af mikroorganisme og kit til detektion af mikroorganisme
DE602005001520D1 (de) Zeiteinstellungssystem und Zeiteinstellungsverfahren
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
EP2162458A4 (en) PROTEIN KINASE BINDING NUCLEOSIDES AND RELATED METHODS
NO20042767L (no) Sammenforingssystem, enkeltelementer og fremgangsmate for bruk av dette
DK1954713T3 (da) Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
DK1502590T3 (da) Heterocykliske oximderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af diabetes type II
ATE417048T1 (de) N-ä3-(3-substituierte pyrazoloä1,5-aüpyrimidin-7- yl)phenylü-sulfonamide, und zusammensetzungen, und damit in zusammenhang stehende verfahren
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
FI20055682A0 (fi) Läpivientiosa sekä menetelmä
DE602006019849D1 (de) Proteinspaltungsverfahren und verwendung davon